Holen Sie sich die Stockscreener-App
6.19
4.48%
-0.29
Personalis Inc Aktie (PSNL) Neueste Nachrichten
What drives Personalis Inc. stock priceMassive profits - Autocar Professional
Is Personalis Inc. a good long term investmentFree Stock Market Forecast Reports - Autocar Professional
Personalis Inc. Stock Analysis and ForecastExplosive trading opportunities - Jammu Links News
What analysts say about Personalis Inc. stockFree Wealth Management Insights - Jammu Links News
Personalis Strengthens Leadership: New VP Gets $631K Stock Option Package in Precision Oncology Push - Stock Titan
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PSNL Stock News - GuruFocus
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Tempus AI, Inc. (TEM) and Personalis Join Forces to Take on Colorectal Cancer - Insider Monkey
From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine - Benzinga
How Personalis Inc. stock performs during market volatilityFree Access to Community with 300% Return - Newser
Why Personalis Inc. stock attracts strong analyst attentionFree Insider Trading Tips - Newser
What makes Personalis Inc. stock price move sharplyFree Investment Group - Newser
Personalis (NASDAQ:PSNL) Pulls Back 14% This Week, but Still Delivers Shareholders Splendid 284% Return Over 1 Year - 富途牛牛
Personalis, Inc. (PSNL) Stock Analysis: Navigating a 5.50% Revenue Growth Amidst Volatility - DirectorsTalk Interviews
Personalis (PSNL) Expands Partnership with Tempus AI for Cancer Detection - GuruFocus
Personalis and Tempus: Pioneering the Future of Colorectal Cancer Care Through Precision Diagnostics - AInvest
Personalis expands Tempus deal to include colorectal cancer testing - Seeking Alpha
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - businessnewsthisweek.com
Personalis and Tempus extend cancer detection collaboration to 2029 By Investing.com - Investing.com South Africa
Personalis and Tempus: A Cancer Detection Breakthrough with Multi-Billion-Dollar Implications - AInvest
Personalis extends Tempus agreement to add colorectal cancer indication By Investing.com - Investing.com South Africa
Personalis and Tempus extend cancer detection collaboration to 2029 - Investing.com Australia
Personalis Expands Tempus Strategic Collaboration to Bring Ultra - GuruFocus
Personalis extends Tempus agreement to add colorectal cancer indication - Investing.com
Personalis Expands Agreement with Tempus AI for Cancer Test - TipRanks
Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer - HIT Consultant
Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer Detection - MarketScreener
Personalis Expands Tempus Strategic Collaboration to Bring Ultra-S Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients - MarketScreener
Personalis (PSNL) Surges 14.2%: Is This an Indication of Further Gains? - MSN
Supernus Pharmaceuticals (NASDAQ:SUPN) & Personalis (NASDAQ:PSNL) Financial Comparison - Defense World
Personalis, Inc.(NasdaqGM: PSNL) added to Russell Small Cap Completeness Index - MarketScreener
Personalis, Inc.(NasdaqGM: PSNL) added to Russell 3000 Index - MarketScreener
3.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):